Dataset Information

HNCDB: An Integrated Gene and Drug Database for Head and Neck Cancer.

ABSTRACT: Head and neck cancer (HNC) is the sixth most common cancer worldwide. Over the last decade, an enormous amount of well-annotated gene and drug data has accumulated for HNC. However, a comprehensive repository is not yet available. Here, we constructed the Head and Neck Cancer Database (HNCDB: http://hncdb.cancerbio.info) using text mining followed by manual curation of the literature to collect reliable information on the HNC-related genes and drugs. The high-throughput gene expression data for HNC were also integrated into HNCDB. HNCDB includes the following three separate but closely related components: "HNC GENE," "Connectivity Map," and "ANALYSIS." The "HNC GENE" component contains comprehensive information for the 1,173 HNC-related genes manually curated from 2,564 publications. The "Connectivity Map" includes information on the potential connections between the 176 drugs manually curated from 2,032 publications and the 1,173 HNC-related genes. The "ANALYSIS" component allows users to conduct correlation, differential expression, and survival analyses in the 2,403 samples from 78 HNC gene expression datasets. Taken together, we believe that HNCDB will be of significant benefit for the HNC community and promote further advances for precision medicine research on HNC.

SUBMITTER: Zhang Q

PROVIDER: S-EPMC6527845 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

HNCDB: An Integrated Gene and Drug Database for Head and Neck Cancer.

Zhang Qingbin Q Li Xingyang X Su Xuan X Zhang Hongwan H Wang Hanbing H Yin Sanjun S Pei Xiaoqing X Yang Ankui A Zuo Zhixiang Z

Frontiers in oncology 20190514

Head and neck cancer (HNC) is the sixth most common cancer worldwide. Over the last decade, an enormous amount of well-annotated gene and drug data has accumulated for HNC. However, a comprehensive repository is not yet available. Here, we constructed the Head and Neck Cancer Database (HNCDB: http://hncdb.cancerbio.info) using text mining followed by manual curation of the literature to collect reliable information on the HNC-related genes and drugs. The high-throughput gene expression data for ...[more]

PMID: 31139565

Similar Datasets

Project description:ImportanceAlthough a few studies have shown that mental health disorders (MHDs) are strongly associated with the 5-year survival and recurrence rates in patients with head and neck cancer (HNC), none have been replicated in a large-scale study.ObjectiveTo describe the prevalence of MHDs in patients with HNC and the potential associations with survival and recurrence using a large insurance claims database.Design, setting, and participantsThis retrospective cohort study assessed data queried from the MarketScan database from January 1, 2005, through December 31, 2014, for 52 641 patients with a diagnosis of HNC. To exclude patients with a preexisting HNC diagnosis or those with incomplete data, patients were included if they were in the database for at least 12 months before the index diagnosis and continuously enrolled. Data were analyzed from February 20, 2017, through January 22, 2019.Main outcomes and measuresTo compare the frequency of MHDs before and after diagnosis of HNC, χ2 tests for independence were used. Adjusted adds ratios (aORs) were obtained using multivariable logistic regression by comparing the prevalence of MHDs in patients with oral cavity cancer and those with other cancer sites in the head and neck.ResultsAmong the 52 641 patients included in the analysis (mean [SD] age, 51.31 [9.79] years), men (58.5%), patients aged 55 to 64 years (46.6%), and those from the South (40.3%) were most commonly affected by HNC. Oral cavity cancers (40.4%) were the most common type, followed by cancers of the oropharynx (19.2%) and larynx (15.5%). Of the various cancer sites, the OR for MHD prevalence was significantly increased in patients with cancers of the trachea compared with the oral cavity (2.11; 95% CI, 1.87-2.38). The prevalence of MHDs in patients with HNC increased to 29.9% compared with 20.6% before the cancer diagnosis. Specifically, women (adjusted OR, 1.58; 95% CI, 1.49-1.67) and patients with a history of tobacco use (adjusted OR, 1.42; 95% CI, 1.34-1.50) and alcohol use (adjusted OR, 1.56; 95% CI, 1.38-1.76) had significantly higher odds of MHDs after the diagnosis of HNC.Conclusions and relevanceAlthough the baseline MHD prevalence of 20.6% before the cancer diagnosis was close to the national average (17.9% according to the National Survey on Drug Use and Health), results of this study showed that it increased to 29.9% after the cancer diagnosis. Women and patients with a history of tobacco and alcohol use were most susceptible to being diagnosed with an MHD. There is an association between patients with HNC and an increased prevalence of MHDs after treatment compared with the general population.

Dataset Information

HNCDB: An Integrated Gene and Drug Database for Head and Neck Cancer.

Publications

HNCDB: An Integrated Gene and Drug Database for Head and Neck Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets